FDA Chief Warns US Losing Ground to China in Early Drug Development

The FDA chief warns that the U.S. is falling behind China in early drug development and calls for faster trial approvals to address bottlenecks in hospital contracting, ethical reviews, and Investigational New Drug applications.

18 Feb, 20:35 — 18 Feb, 22:00

Post Share

Perspective Analysis

AI-generated comparison of how 2 sources cover this story

Both outlets cover the FDA's efforts to accelerate drug development, acknowledging the need for faster approvals. CNBC emphasizes the FDA chief's warning about losing ground to China and details specific bottlenecks, while Associated Press News highlights a concrete FDA policy change to drop the two-study requirement. The coverage is aligned on the overarching goal but diverges in the specific aspects of the story they prioritize.

What sources agree on

The FDA aims to speed up drug approvals.
There is a recognized need for faster trial approvals.

Where they diverge

The primary focus regarding the acceleration of drug development.

cnbc

This outlet frames the issue around the FDA chief's warning about losing ground to China and identifies specific bottlenecks hindering the process.

Associated Press News

This outlet focuses on a specific FDA policy change, the dropping of the two-study requirement, as a means to speed up access to new drugs.

Notable gaps

The identification of specific bottlenecks such as hospital contracting, ethical reviews, and Investigational New Drug applications.

Covered by cnbc · Not in Associated Press News

The FDA's decision to drop the two-study requirement for new drug approvals.

Covered by Associated Press News · Not in cnbc

Perspective Analysis

Comparing sources…

Coverage Timeline

cnbc18 Feb, 20:35First to report

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

AP18 Feb, 22:00

FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News

Read at source (2 outlets)

AP2h ago

FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News

FDA will drop two-study requirement for new drug approvals, aiming to speed access Associated Press News

Read full article →

cnbc3h ago

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug applications process

Read full article →

PERSPECTA

FDA Chief Warns US Losing Ground to China in Early Drug Development

Perspective Analysis

What sources agree on

Where they diverge

Notable gaps

Perspective Analysis

Coverage Timeline

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News

Read at source (2 outlets)

FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Related Stories

71-Year-Old Farmer Becomes Pilates Pin-Up for Middle-Aged Men

Tommy Lee Jones' Daughter Dies of Accidental Overdose

Texas Tech Medical School Cancels Talk on Late-Pregnancy Abortions

71-Year-Old Farmer Becomes Pilates Pin-Up for Middle-Aged Men

Perspective Analysis

What sources agree on

Where they diverge

Notable gaps